Phase 4 N=113 Anti-HIV Medications for People Recently Infected With HIV
HIV Infections
Primary: Total Treatment-free Time to Initiation of Permanent HAART — 18; 18 months
Clinical Trial Search
Completed trials with posted results — search by concept, filter by the parameters that matter at the bedside.
Phase 4 N=168 Safety, Tolerability, and Immunogenicity of Vaxelis™ in Children Previously Vaccinated With Vaxelis™ or Hexyon™ (V419-016)
Vaccines, Combined · Hexavalent Vaccine
Primary: Percentage of Participants With a Solicited Injection-site Adverse Event (AE) — 52.9; 50.0; 74.1; 56.1 Percentage of participants
Phase 4 N=390 Pre-hospital Administration of Thrombolytic Therapy With Urgent Culprit Artery Revascularization
Heart Disease · Myocardial Infarction · Acute Myocardial Infarction
Primary: Mortality at 30 Days — 1; 7; 3; 2 participants
Phase 4 N=136 Ancillary Effects of Oral Naloxegol (Movantik)
Pain, Postoperative
Primary: Residual Urine Volume — 62; 114; 48; 31 ml — p=0.84
Phase 4 N=65 Postoperative Pain Control in Septum and Sinus Surgery
Post-operative Pain · Sinus Surgery
Primary: Number of Doses of Opiate (Narcotic) Pain Medication — 1.0; 1.5 number of doses
Phase 4 N=41 Disulfiram Combined With Lorazepam for Alcohol Dependence and Anxiety Disorder
Alcohol Dependence · Anxiety Disorder
Primary: Treatment Adherence — 15 Participants
Phase 4 N=89 Effects of Donepezil HCL on Task-Activated fMRI Brain Activation in Healthy Older Adults at Genetic Risk for Alzheimer's Disease
Genetic Risk for Alzheimer's Disease
Primary: Change in BOLD Response From Baseline to 24 Weeks During Functional Magnetic Resonance Imaging - Left Posterior Cingulate BOLD Signal at 24 Weeks, Adjusting for Baseline…
Phase 4 N=40 Intravenous Iron vs. Oral Iron Supplementation for Postpartum Anemia
Anemia, Iron Deficiency · Delivery Complication
Primary: Hemoglobin Level — 12; 12 grams/deciliters
Phase 4 N=225 HPV Vaccination Study in Postpartum Women
HPV · Immunization · Human Papilloma Virus
Primary: Immunogenicity of a Two-dose 9-valent HPV Vaccination as Assessed by Antibody Titer — 7177.6 mMU/mL
Phase 4 N=64 Assessing Success of MTA and Pre-mixed Bioceramic in Mature Teeth With Irreversible Pulpitis With Full Pulpotomy.
Pulpitis - Irreversible
Primary: Clinical Success at 6 Months — 27; 30 Participants
Phase 4 N=10 Examining the Effect of Burosumab on Muscle Function
X-linked Hypophosphatemia
Primary: Skeletal Muscle Adenosine Triphosphate (ATP) Synthesis Rate — 9.41 umol/g/min — p=0.4147
Phase 4 N=80 Efficacy of Dextenza Insert in Upper vs Lower Punctum Following Cataract Surgery With PCIOL.
Cataract
Primary: Participants With Complete Absence of Ocular Pain at Day 8 — 39; 39; 0; 1 Participants
Phase 4 N=453 Sustained Effect of Droxidopa in Symptomatic Neurogenic Orthostatic Hypotension
Symptomatic Neurogenic Orthostatic Hypotension
Primary: Time To Intervention — 52.00; 42.00; NA; NA Days — p=0.803
Phase 4 N=28 Effect of Renin-angiotensin-system Blockade on Urinary Free Light Chains in Patients With Type 2 Diabetes Mellitus
Type 2 Diabetes · Hypertension
Primary: Change in Urine Microalbumin Creatinine Ratio — 15 mg/g
Phase 4 N=61 Impact of Chronic Kidney Disease on Clopidogrel Effects in Diabetes Mellitus
Chronic Kidney Disease (CKD) · Type 2 Diabetes Mellitus (T2DM) · Coronary Artery Disease (CAD)
Primary: Platelet Reactivity Index (PRI) Assessed by VASP. The Cutoff for High Platelet Reactivity is >50% — 67.5; 67.2 PRI%